C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
Petros Grivas,Neeraj Agarwal,Sumanta K. Pal,Arash Rezazadeh Kalebasty,Srikala S. Sridhar,Jodi Smith,Geeta Devgan,Cora N. Sternberg,Joaquim Bellmunt +8 more
TL;DR: Avelumab 1L maintenance is also included as a standard of care in treatment guidelines for advanced urothelial carcinoma (UC) with level 1 evidence as discussed by the authors, however, trials of 1L ICI monotherapy or chemotherapy+ICI combinations have not yet shown improved overall survival vs chemotherapy alone.
Journal ArticleDOI
Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors
Cora N. Sternberg,P.H.M. de Mulder,Jan H. Schornagel,Christine Theodore,Sophie D. Fosså,A. van Oosterom,F. Witjes,Michele Spina,C.J. van Groeningen,C. de Balincourt,L. Collette +10 more
TL;DR: Using an intent-to-treat analysis, on the HD M-VAC arm there were 28 CRs (21%) and 55 PRs (41%), for an overall RR of 62% (95%CI 54% to 70%).
Journal ArticleDOI
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
M. Bolla,L. Collette,Leo E.C.M. Blank,Padraig Warde,J.B Dubois,R.O. Mirimanoff,Guy Storme,Jacques Bernier,Abraham Kuten,Cora N. Sternberg,J Mattelaer,J Lopez Torecilla,J.R Pfeffer,C Lino Cutajar,A Zurlo,Marianne Pierart,Mark A. Ritter +16 more
Journal ArticleDOI
Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy
Scott T. Tagawa,Arjun Vasant Balar,Daniel P. Petrylak,Petros Grivas,Neeraj Agarwal,Cora N. Sternberg,Q. Hong,A. Gladden,C. Kanwal,P. Siemon-Hryczyk,T. Goswami,L.M. Itri,Y. Loriot +12 more
Journal ArticleDOI
Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-α as second-line treatment of advanced transitional cell cancer of the urothelial tract
P.H.M. de Mulder,Christine Theodore,Avishay Sella,O. Koriakine,Cora N. Sternberg,Laurence Collette,C. de Balincourt +6 more
TL;DR: This combination can not be recommended as second line treatment for metastatic transitional-cell carcinoma of the urothelial tract due to major toxicity and two toxic deaths.